AASB 139 - Financial Instruments: Recognition and Measurement - July 2004
End of month 2 (28 February 20x1)End of month 2 (28 February 20x1)
Start here
Get a plain-English read of End of month 2 (28 February 20x1)
Turn the raw legal text into a practical explanation grounded in AASB 139 - Financial Instruments: Recognition and Measurement - July 2004.
End of month 2 (28 February 20x1)
IE23 On 28 February 20x1 when Entity A next tests effectiveness, LIBOR is unchanged. Entity A does not revise its prepayment expectations. The fair value of the designated interest rate swap with a notional principal of CU8 million is (CU9,518)[12] (the swap is a liability). Also, Entity A calculates the fair value of the CU8 million of the hedged assets as at 28 February 20x1 as CU8,009,518.[13]
IE24 Entity A makes the following accounting entries relating to the hedge in this time period:
Dr Cash CU71,707
Cr Profit or loss (interest income) CU71,707
To recognise the interest received on the hedged amount (CU8 million).
Dr Profit or loss (interest expense) CU71,707
Cr Profit or loss (interest income) CU62,115
Cr Cash CU9,592
To recognise the interest received and paid on the portion of the swap designated as the hedging instrument (CU8 million).
Dr Derivative liability CU9,445
Cr Profit or loss (gain) CU9,445
To recognise the change in the fair value of the portion of the swap designated as the hedging instrument (CU8 million) (CU9,518 – CU18,963)
Dr Profit or loss (loss) CU9,445
Cr Separate line item in the
statement of financial position CU9,445
To recognise the change in the fair value of the hedged amount (CU8,009,518 – CU8,018,963).
IE25 The net effect on profit or loss (excluding interest income and interest expense) is nil reflecting that the hedge is fully effective.
IE26 Entity A makes the following accounting entry to amortise the line item balance for this time period:
Dr Profit or loss (loss) CU11,378
Cr Separate line item in the
statement of financial position CU11,378[14]
To recognise the amortisation charge for the period.